COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
- Conditions
- Kidney TransplantCOVID-19
- Interventions
- Biological: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-03-24
- Target Recruit Count
- 80
- Registration Number
- NCT05518487
- Locations
- πΊπΈ
University of California San Diego Medical Center: Transplantation, San Diego, California, United States
πΊπΈEmory University School of Medicine: Transplantation, Atlanta, Georgia, United States
πΊπΈUCSF School of Medicine: Transplantation, San Francisco, California, United States
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-04-20
- Target Recruit Count
- 229
- Registration Number
- NCT05512949
- Locations
- πΊπΈ
Brigham and Women's Hospital, Boston, Massachusetts, United States
πΊπΈUniversity of California, San Diego (UCSD) - Antiviral Research Center (AVRC), San Diego, California, United States
πΊπΈVanderbilt University Medical Center, Nashville, Tennessee, United States
Safety and Immunogenicity of CJCV2 With and Without ALFQ
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2025-01-17
- Target Recruit Count
- 59
- Registration Number
- NCT05500417
- Locations
- πΊπΈ
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
- Conditions
- Ebola Virus Disease
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-03-30
- Target Recruit Count
- 203
- Registration Number
- NCT05494801
- Locations
- π±π·
John F. Kennedy Medical Center, Monrovia, Liberia
A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults
- Conditions
- HIV
- Interventions
- Biological: Trimer 6931 (100 mcg)Biological: FP conjugate vaccine (200 mcg)Biological: FP conjugate vaccine (25 mcg)Biological: Trimer 4571 (200 mcg)Biological: Trimer 6931 (200 mcg)Biological: Trimer 4571 (100 mcg)
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2025-03-21
- Target Recruit Count
- 44
- Registration Number
- NCT05470400
- Locations
- πΊπΈ
BIDMC Vcrs [32077], Boston, Massachusetts, United States
πΊπΈNew York Blood Center CRS [31801], New York, New York, United States
πΊπΈAtlanta - Hope Clinic, Atlanta, Georgia, United States
Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b Adjuvanted With 3M-052-AF + Alum in Healthy, HIV-1 Uninfected Adult Participants
- Conditions
- HIV-1-infection
- Interventions
- Biological: 426c.Mod.Core-C4b 30 mcgOther: PlaceboBiological: BG505Biological: 426c.Mod.Core-C4b 100 mcgBiological: 426c.Mod.Core-C4b 300 mcg
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2023-11-30
- Target Recruit Count
- 52
- Registration Number
- NCT05471076
- Locations
- πΊπΈ
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
πΊπΈBridge HIV CRS, San Francisco, California, United States
πΊπΈSeattle Vaccine and Prevention CRS, Seattle, Washington, United States
Neonatal Phase 1 Valacyclovir Study
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 16
- Registration Number
- NCT05468619
- Locations
- πΊπΈ
Children's Nebraska, Omaha, Nebraska, United States
πΊπΈNationwide Children's Hospital, Columbus, Ohio, United States
πΊπΈChildren's of Alabama Child Health Research Unit (CHRU), Birmingham, Alabama, United States
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Biological: Pheripheral blood stem cellsDrug: TociluzumabDrug: Emapalumab-IzsgDrug: Total Body Irradiation
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 50
- Registration Number
- NCT05463133
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa
- Conditions
- Bacterial Disease CarrierCystic Fibrosis
- Interventions
- Other: Placebo
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 72
- Registration Number
- NCT05453578
- Locations
- πΊπΈ
The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States
πΊπΈUniversity of California, San Diego, La Jolla, California, United States
πΊπΈUniversity of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States
Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model
- Conditions
- Influenza Infection
- Interventions
- Biological: A/Mallard/Ohio-99/MM4/1989 H10N7
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 35
- Registration Number
- NCT05436444
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States